Skip to content

IVL and RA in Treatment of Balloon-crossable Severely Calcified Coronary Lesions

Intravascular Lithotripsy and Rotational Atherectomy in Treatment of Severely Calcified Coronary Lesions

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04556682
Enrollment
101
Registered
2020-09-21
Start date
2021-05-01
Completion date
2022-02-25
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Calcification

Keywords

IVL, RA

Brief summary

This study to compare periprocedural safety, angiographic success as well as short and long term outcomes of intravascular lithotripsy and rotational atherectomy as a method of severely calcified coronary lesion preparation before DES implantation.

Detailed description

Coronary artery calcification (CAC) occurs in over 90% of men and 67% of women older than 70 years old . Severe coronary calcification may be present in about 20% of patients undergoing percutaneous coronary intervention (PCI) . Coronary calcification may impair stent delivery and expansion and damage the polymer/drug coating, resulting in impaired drug delivery and predispose to restenosis and stent thrombosis. Intravascular imaging as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are good tools to assess calcium burden, distribution and thickness. Among the two imaging techniques, OCT was found to be more accurate than IVUS in defining calcium burden, calcium area , thickness and calcium length. Rotational atherectomy (RA) as a method of severely calcified lesions modification before Drug-Eluting-Stent (DES) implantation has shown good outcomes in recent studies. However, its efficacy is reduced in presence of deep calcification. Recently, intravascular lithotripsy (IVL) has been introduced as a novel modality for severely calcified coronary lesion preparation with good preliminary outcomes . Currently the two techniques are regularly being used in combination in order to achieve optimal results . Whether IVL is a method equally good (or superior) to rotablation in cases where anatomy does not exclude the use of either technique (for example balloon-crossable, heavily calcified lesions) has not yet been discussed.

Interventions

Device used for severely calcified coronary lesion preparation before stent implantation.

Device used for severely calcified coronary lesion preparation before stent implantation.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients aged \>18 years undergoing PCI because of stable angina (uncontrolled symptoms on optimal medical treatment) or post stabilized acute coronary syndrome (ACS). * Patients have severe calcification: defined either angiographically or by OCT (or IVUS) as calcium arch \>180º in at least one cross section , calcium length \>5mm, calcium thickness \>0.5 mm (2, 6). * Vessel diameter ≥2.5mm and ≤4.0mm . * Heavily calcified lesion length less than 40mm. * All patients must have been discussed in the heart team of the hospital and accepted for coronary intervention

Exclusion criteria

* Severe coronary calcification with lesion uncrossable from a balloon. * PCIs in the setting of STEMI or NSTEMI with persistent complains. * Patients in cardiogenic shock. * Heart failure New York Heart Association (NYHA) class IV.

Design outcomes

Primary

MeasureTime frameDescription
Strategy successUp to one dayless than 20% in-stent residual stenosis of the target lesion and no postprocedural complications as no-reflow, dissection or perforation.

Secondary

MeasureTime frameDescription
Major Adverse Cardiac Eventsafter one yearcomposite of Death, stroke, myocardial infarction, stent thrombosis, target vessel revascularization, and hospitalization at long term follow up

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026